Monitor the MAPLE-HCM late-breaking data at the congress (May 11) for potential differentiation vs. metoprolol, but this is a scientific meeting update with no immediate stock-moving catalyst. Watch for future regulatory decisions in additional geographies or label expansions.
Price Chart
Executive Summary
Cytokinetics announced nine presentations at the ESC Heart Failure 2026 Congress, including a late-breaking oral presentation on the MAPLE-HCM study comparing aficamten to metoprolol in obstructive HCM. The presentations highlight ongoing clinical data generation for MYQORZO (aficamten), which is already approved in the U.S., EU, and China for oHCM, but no new regulatory or commercial catalysts were disclosed.
Key Facts
- Nine presentations at ESC Heart Failure 2026 Congress (May 9–12, 2026) including a late-breaking oral presentation on MAPLE-HCM study comparing aficamten vs. metoprolol in oHCM.
- MYQORZO (aficamten) is approved in U.S., EU, and China for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Aficamten is under investigation in Phase 3 trials for non-obstructive HCM (ACACIA-HCM) and pediatric oHCM (CEDAR-HCM).
- No new regulatory decisions, financial results, or commercial updates were provided in this press release.
Financial Impact
No financial figures disclosed; scientific conference presentations are routine and do not directly impact revenue or earnings.
Risk Factors
- Competition from existing oHCM therapies (e.g., mavacamten) could limit MYQORZO market share.
- Clinical trial results for nHCM or pediatric indications may not meet endpoints.
- Regulatory setbacks in new indications or geographies could impact revenue expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access